The NUVISAN History

Foundation of NUVISAN ICB GmbH and takeover of a fully equipped pharmaceutical research unit with 400 workplaces in the field of small-molecule active ingredients from Bayer.

NUVISAN expended its portfolio to phase II patient trials by acquiring the CRO INAMED in Gauting near Munich.

Market entry into Chemistry and Formulation development. NUVISAN acquired from NESTLÉ SKIN HEALTH parts of the GALDERMA research activities at Sophia Antipolis, France.

Foundation of NUVISAN Inc., a subsidiary of NUVISAN GmbH, in Boston, Massachusetts USA.

Entry into Non-Clinical development by the acquisition and integration of the Grafing site from the long-standing partner Merck KGaA.

Expansion to Waltrop Germany by taking over the research institute Essex Pharma from MSD. Integration of large-scale stability programs and services. Expansion into pharmaceutical analysis of hormones, polymers and large molecules.

Foundation as NUVISAN GmbH after sale of the AAIPharma group of companies to new owners.

The company now traded under the name AAIPharma Deutschland. The company was renamed AAIPharma in the USA at the same time as AAI International.

Takeover by AAI International (Wilmington, NC). The company is a US-based multi-functional contract research organization providing GCP, GLP and GMP-related services to the pharmaceutical industry to support early to late product development.

LAB GmbH was founded as one of the first German contract research institutions for the clinical development of the pharmaceutical industry. In the early clinical phase, the company quickly developed into a full-service provider.